The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Food and Drug Administration ("FDA") for DAXI to treat glabellar (frown) lines (the "DAXI BLA"). In November 2019, Revance issued a press release announcing that it had submitted a Biologics License Application ("BLA") to the U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |